OncoMatch/Clinical Trials/NCT07223307
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Is NCT07223307 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for liver cancer.
Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Cholangiocarcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radioembolization
Prior treatment with radioembolization
Cannot have received: radiotherapy
Exception: if overlapping with study treatment site
Prior radiotherapy overlapping with study treatment site
Lab requirements
Liver function
child-pugh a status
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Palo Alto, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07223307 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radioembolization, radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify